Nonprofit · EIN 52-2122720
FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA
Tax-exempt · DOWNINGTOWN, PA 19335
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2024 | 990 | $13,135,426 | $13,277,236 | -$141,810 | $6,946,549 | $676,182 | $6,270,367 |
| December 31, 2023 | 990 | $11,203,043 | $12,200,773 | -$997,730 | $7,752,276 | $1,605,648 | $6,146,628 |
Financial details: 990 for the year ended December 31, 2024
Revenue
- Contributions, gifts and grants
- $13,517,065
- Program service revenue
- $0
- Investment income
- $172,331
- Net gain from sales of assets
- $26,710
- Net income from fundraising events
- -$553,970
- Other revenue
- -$553,970
Expenses
- Grants and similar amounts paid
- $10,467,810
- Compensation of officers, directors and key employees
- $352,453
- Other salaries and wages
- $1,005,136
- Salaries, compensation and benefits (total)
- $1,572,657
- Professional fundraising fees
- $0
- Accounting fees
- $28,777
- Occupancy
- $47,789
- Program services (functional)
- $12,534,019
- Management and general (functional)
- $374,757
- Fundraising (functional)
- $368,460
Balance sheet and other
- Total assets, start of year
- $7,752,276
- Total assets, end of year
- $6,946,549
- Total liabilities, end of year
- $676,182
- Net assets, end of year
- $6,270,367
- Publicly traded securities
- $1,705,100
- Net assets without donor restrictions
- $3,919,967
- Net assets with donor restrictions
- $2,350,400
- Gross receipts
- $14,956,926
- Employees
- 19
- Volunteers
- 500
- Year formed
- 1998
- State of legal domicile
- VA
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2024, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| BARBARA A TATE | CHIEF SCIENTIFIC OFFICER Highest-paid employee | 40 | $250,000 | $5,527 |
| JENNIFER M FARMER | CHIEF EXECUTIVE OFFICER Officer | 40 | $165,000 | $5,678 |
| ELISABETTA SORAGNI | DIRECTOR OF RESEARCH Highest-paid employee | 40 | $115,851 | $16,023 |
| FELICIA DEROSA | VP FUNDRAISING & COMMS Highest-paid employee | 40 | $106,351 | $12,292 |
| RONALD BARTEK | PRESIDENT/DIRECTOR Trustee or director, Officer | 40 | $110,000 | $3,811 |
| RUTH ACTON | TREASURER/DIRECTOR FINANCE Trustee or director, Officer | 25 | $51,000 | $16,964 |
| PAUL AVERY | CHAIRMAN/ DIRECTOR Trustee or director, Officer | 10 | $0 | $0 |
| MAUREEN JUIP | SECRETARY/ DIRECTOR Trustee or director, Officer | 10 | $0 | $0 |
| DR SANJAY BIDICHANDANI | DIRECTOR Trustee or director | 10 | $0 | $0 |
| BRIGID BRENNAN | DIRECTOR/ GENERAL COUNSEL Trustee or director | 20 | $0 | $0 |
| THOMAS BRENNINKMEIJER | DIRECTOR Trustee or director | 10 | $0 | $0 |
| ALEX FIELDING | DIRECTOR Trustee or director | 10 | $0 | $0 |
| JENNIFER GOOD | DIRECTOR Trustee or director | 10 | $0 | $0 |
| THOMAS HAMILTON | DIRECTOR Trustee or director | 10 | $0 | $0 |
| DR HOLLY HEDRICK | DIRECTOR Trustee or director | 10 | $0 | $0 |
8 more people on this return
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| DEREK G HENNECKE | DIRECTOR Trustee or director | 10 | $0 |
| WARREN HUFF | DIRECTOR Trustee or director | 10 | $0 |
| DR STEVE KLASKO | DIRECTOR Trustee or director | 10 | $0 |
| DR KATHY MATHEWS | DIRECTOR Trustee or director | 10 | $0 |
| DR JAMES MCARTHUR | DIRECTOR Trustee or director | 10 | $0 |
| TONY PLOHOROS | DIRECTOR Trustee or director | 10 | $0 |
| PATRICK RITSCHEL | DIRECTOR Trustee or director | 10 | $0 |
| DR JAMES R RUSCHE | DIRECTOR Trustee or director | 10 | $0 |
990 for the year ended December 31, 2023: 22 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| BARBARA A TATE | CHIEF SCIENTIFIC OFFICER Highest-paid employee | 40 | $250,000 | $7,799 |
| JENNIFER M FARMER | CHIEF EXECUTIVE OFFICER Officer | 40 | $167,825 | $5,834 |
| ELISABETTA SORAGNI | DIRECTOR OF RESEARCH Highest-paid employee | 40 | $111,935 | $15,538 |
| RONALD BARTEK | PRESIDENT/DIRECTOR Trustee or director, Officer | 40 | $114,377 | $4,006 |
| FELICIA DEROSA | VP FUNDRAISING & COMMS Highest-paid employee | 40 | $102,261 | $11,840 |
| RUTH ACTON | TREASURER/DIRECTOR FINANCE ADMIN & HR Trustee or director, Officer | 25 | $47,463 | $13,735 |
| MARILYN E DOWNING | SECRETARY/ DIRECTOR Trustee or director, Officer | 10 | $0 | $0 |
| DR SANJAY BIDICHANDANI | DIRECTOR Trustee or director | 10 | $0 | $0 |
| BRIGID BRENNAN | DIRECTOR/ GENERAL COUNSEL Trustee or director | 20 | $0 | $0 |
| THOMAS BRENNINKMEIJER | DIRECTOR Trustee or director | 10 | $0 | $0 |
| ALEX FIELDING | DIRECTOR Trustee or director | 10 | $0 | $0 |
| JENNIFER GOOD | DIRECTOR Trustee or director | 10 | $0 | $0 |
| THOMAS HAMILTON | DIRECTOR Trustee or director | 10 | $0 | $0 |
| DR HOLLY HEDRICK | DIRECTOR Trustee or director | 10 | $0 | $0 |
| DEREK G HENNECKE | DIRECTOR Trustee or director | 10 | $0 | $0 |
| DR STEVE KLASKO | DIRECTOR Trustee or director | 10 | $0 | $0 |
| DR KATHY MATHEWS | DIRECTOR Trustee or director | 10 | $0 | $0 |
| DR JAMES MCARTHUR | DIRECTOR Trustee or director | 10 | $0 | $0 |
| TONY PLOHOROS | DIRECTOR Trustee or director | 10 | $0 | $0 |
| PATRICK RITSCHEL | DIRECTOR Trustee or director | 10 | $0 | $0 |
| DR JAMES R RUSCHE | DIRECTOR Trustee or director | 10 | $0 | $0 |
| PAUL AVERY | CHAIRMAN/ DIRECTOR Trustee or director, Officer | 10 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 533 W UWCHLAN AVE, DOWNINGTOWN, PA 19335-1763
- In care of
- % RONALD J BARTEK
- Principal officer (990 for 2024)
- JENNIFER FARMER, 533 W UWCHLAN AVENUE, DOWNINGTOWN, PA 19335
- Signed the 990
- JENNIFER FARMER, CHIEF EXECUTIVE OFFICER
- Phone
- (484) 879-6160
- Website
- WWW.CUREFA.ORG
- Return prepared by
- EISNER ADVISORY GROUP LLC
Mission
TO MARSHAL AND FOCUS THE RESOURCES AND RELATIONSHIPS NEEDED TO CURE FA BY RAISING FUNDS FOR RESEARCH, PROMOTING PUBLIC AWARENESS AND ALIGNING SCIENTISTS, PATIENTS, CLINICIANS, GOVERNMENT AGENCIES AND PHARMACEUTICAL COMPANIES DEDICATED TO CURING FA AND RELATED DISORDERS.
Program accomplishments
- RESEARCH AND GRANT PROGRAM - SEE SCHEDULE OExpenses $10,330,478 · grants $9,606,747
- CLINICAL RESEARCH INFRASTRUCTUREIN ADDITION TO RESEARCH GRANTS, FARA FUNDS THE ONGOING DEVELOPMENT OF DOMAIN RESOURCES IN THE FORM OF VITAL CLINICAL RESEARCH INFRASTRUCTURE. CLINICAL RESEARCH INFRASTRUCTURE REFERS TO THE RESOURCES NEEDED TO FACILITATE ANY TYPE OF RESEARCH, INCLUDING CLINICAL TRIALS THAT INVOLVE PATIENTS. THESE RESOURCES INCLUDE PROGRAMS LIKE: FRIEDREICH'S ATAXIA GLOBAL PATIENT REGISTRY: THE FRIEDREICH'S ATAXIA GLOBAL PATIENT REGISTRY (FAGPR) IS THE ONLY WORLDWIDE REGISTRY OF FRIEDREICH'S ATAXIA PATIENTS. THE GOALS OF THE FAGPR ARE TO COLLECT INFORMATION ON ALL FA PATIENTS IN ONE REGISTRY, TO DEVELOP THE REGISTRY INTO A POWERFUL RESOURCE FOR RESEARCH, AND TO ENGAGE THE FA COMMUNITY IN STUDIES AIMED AT ADVANCING OUR KNOWLEDGE (CONTINUED IN SCHEDULE O)CLINICAL RESEARCH INFRASTRUCTURE (CONT'D):OF FA AND THE TREATMENTS BEING DEVELOPED. FARA PARTNERS WITH INTERNATIONAL PATIENT ADVOCACY ORGANIZATIONS THROUGH A GOVERNANCE BOARD TO ENSURE MULTI-STAKEHOLDER ENGAGEMENT AND OVERSIGHT OF THE FAGPR. MORE THAN 1000 INDIVIDUALS WITH FA ARE ENROLLED AND FAGPR WAS USED TO RECRUIT FOR SEVERAL CLINICAL TRIALS AND MANY CLINICAL RESEARCH STUDIES. TO LEARN MORE, VISIT CUREFA.NET/REGISTRY. FA GLOBAL CLINICAL CONSORTIUM: FARA AND THE FA COMMUNITY'S DEDICATION TO COLLECTING NATURAL HISTORY STUDY DATA OVER THE PAST TWO DECADES PROVED INSTRUMENTAL IN THE APPROVAL OF THE FIRST-EVER TREATMENT FOR FA. THROUGH THE FA GLOBAL CLINICAL CONSORTIUM (FA GCC), FARA HAS REDOUBLED ITS INVESTMENT IN NATURAL HISTORY DATA BY ENABLING THE TRANSITION TO AN INDUSTRY-LEADING DATA COLLECTION PLATFORM AND A UNIFIED GLOBAL NATURAL HISTORY PROTOCOL (UNIFAI) RESULTING FROM THE HARMONIZATION OF TWO WELL-ESTABLISHED NATURAL HISTORY STUDIES, THE FA CLINICAL OUTCOME MEASURES STUDY (FA-COMS) AND THE EUROPEAN FRIEDREICH'S ATAXIA CONSORTIUM FOR TRANSLATIONAL STUDIES (EFACTS). THE FA GCC AND THE UNIFAI STUDY HAVE BEEN EXPANDED TO MAKE PATIENT CONTRIBUTIONS TO NATURAL HISTORY EVEN MORE POWERFUL IN UNDERSTANDING FA, EVALUATING THE IMPACT OF TREATMENT OPTIONS FOR FA, ACCELERATING THE DEVELOPMENT OF NEW THERAPIES AND IMPROVING OUTCOMES FOR THOSE LIVING WITH FA. AT EACH UNIFAI STUDY VISIT THERE ARE MORE THAN 1400 DATA ELEMENTS RECORDED. OVER THE LAST TWO YEARS, THE FA GCC HAD ACTIVE PARTICIPATION FROM 54 INVESTIGATORS FROM 33 SITES REPRESENTING 18 COUNTRIES ALONG WITH REPRESENTATIVES FROM PATIENT ADVOCACY AND RESEARCH ORGANIZATIONS. FA GCC RESEARCH ACTIVITIES: THE FA GCC LEADERSHIP IDENTIFIED INITIAL SCIENTIFIC PRIORITIES AND CREATED WORKGROUPS TO ADDRESS THESE PRIORITIES. THE FOLLOWING WORK GROUPS, EACH MADE UP OF 5-10 CONSORTIUM MEMBERS, MET REGULARLY TO ADDRESS GAPS IN CURRENT FA RESEARCH: CARDIAC NATURAL HISTORY, LATE-STAGE SYMPTOMS, PEDIATRIC / PRESYMPTOMATIC, BIO-SAMPLES, MOOD AND COGNITION, AND PATIENT ADVOCACY/ADVISORY TEAM. QUARTERLY FULL GROUP MEETINGS SERVE AS A PLATFORM FOR INVESTIGATORS TO ESTABLISH COMMON RESEARCH INTERESTS, FORM COLLABORATIONS, AND SHARE THEIR GLOBAL EXPERIENCES WITH OMAVELOXOLONE. IMPACT AND FUTURE DIRECTION: THE CONSORTIUM HAS A LONG-TERM OBJECTIVE OF FOSTERING MULTILATERAL RESEARCH AND COLLABORATION ACROSS CONTINENTS, UNIFYING GLOBAL OPINIONS TO REGULATORS AND INDUSTRY PARTNERS, ACCELERATING THE DEVELOPMENT OF NEW THERAPIES, AND IMPROVING OUTCOMES FOR THOSE LIVING WITH FA. ADDITIONAL INFORMATION ABOUT FARA'S PROGRAMS IN 2024 CAN BE ACCESSED VIA THE ANNUAL REPORT AT: CUREFA.ORGExpenses $1,354,745 · grants $781,063
- AWARENESS, EDUCATION, AND OUTREACH PROGRAMS:AWARENESS: FRIEDREICH ATAXIA (FA) IS A RARE DISEASE; AFFECTING 1 IN 50,000 INDIVIDUALS. FARA IS DEDICATED TO ADVOCACY AND RAISING AWARENESS FOR FA. FARA HAS UTILIZED BOTH TRADITIONAL AND SOCIAL MEDIA STRATEGIES TO BRING GREATER AWARENESS TO FA IN THE GENERAL PUBLIC AND TO ENGAGE AND EDUCATE THE FA COMMUNITY. FOR EXAMPLE, FARA CONDUCTS AN ANNUAL A SOCIAL MEDIA CAMPAIGN THAT ENCOURAGES COMMUNITY PARTICIPATION LEADING UP TO FA AWARENESS DAY. ADVOCACY: FARA AND THE NATIONAL ATAXIA FOUNDATION (NAF) PARTNERED ON SEVERAL ADVOCACY INITIATIVES RELEVANT TO THE ATAXIA COMMUNITY. MOSTLY NOTABLY, THE EFFORTS OF THE TWO ORGANIZATIONS RESULTED IN THE CONTINUED INCLUSION OF HEREDITARY ATAXIA AS PART OF (CONTINUED IN SCHEDULE O)ADVOCACY: (CONT'D)THE CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAM (CDMRP) AT THE DEPARTMENT OF DEFENSE IN FISCAL YEAR (FY) 24, RESULTING IN FOUR HEREDITARY ATAXIA RESEARCH GRANTS BEING RECOMMENDED FOR FUNDING TOTALING OVER $12 MILLION. FARA AND NAF WERE ALSO SUCCESSFUL IN GETTING A RESOLUTION PASSED DECLARING SEPTEMBER 25, 2024 NATIONAL ATAXIA AWARENESS DAY AND HOSTING THE SIXTH UNITED AGAINST ATAXIA HILL DAY- WITH 94 CONGRESSIONAL MEETINGS FEATURING THE PARTICIPATION OF 113 FARA AND NAF ADVOCATES FROM 32 STATES. EDUCATION: IN AN ONGOING EFFORT TO SHARE INFORMATION AND EDUCATION, FARA LAUNCHED A NEW WEBSITE IN 2024. THE SITE REDESIGN PRIORITIZED THE USER EXPERIENCE FOR KEY STAKEHOLDERS INCLUDING PATIENT FAMILIES, RESEARCHERS, AND DONORS. THE NEW SITE COINTAINS UP-TO-DATE INFORMATION ON FA RESEARCH INCLUDING GRANTS FUNDED BY FARA, TREATMENT APPROACHES AND PROGRAMS IN THE DRUG DEVELOPMENT PIPELINE, RESEARCH RESOURCES, AND CLINICAL TRIAL OPPORTUNITIES. IT ALSO OFFERS GUIDANCE FOR FAMILIES NAVIGATING FA AND OPPORTUNITIES TO CONNECT WITH OTHERS AND GET INVOLVED.ENGAGING WITH STAKEHOLDERS: AS EXPERTS IN LIVING WITH FA, INDIVIDUALS AND FAMILIES SHARED THEIR STORIES IN MANY FORUMS AND TO MANY AUDIENCES. IN 2024, OVER 50 INDIVIDUALS FROM THE FA COMMUNITY WORKED WITH FARA TO ENGAGE WITH PHARMACEUTICAL PARTNERS, RESEARCHERS, FUTURE HEALTHCARE PROFESSIONALS, MEDICAID COMMITTEES, AND THE FOOD AND DRUG ADMINISTRATION AT 33 DIFFERENT EVENTS. THEIR VOICES PROVIDE ESSENTIAL INSIGHTS THAT ADVANCE MEANINGFUL AND ACCESSIBLE TREATMENTS. CULTIVATING COMMUNITY: THROUGHOUT 2024, FARA WORKED TO STRENGTHEN THE FA COMMUNITY BY FACILITATING OPPORTUNITIES FOR CONNECTION AND COLLABORATION THROUGH VIRTUAL AND IN-PERSON EVENTS. INDIVIDUALS NEW TO THE FA COMMUNITY HAD THE OPPORTUNITY TO MEET OTHER FA FAMILIES FOR THE FIRST TIME. THE FARA AMBASSADOR PROGRAM, A GROUP OF ADULTS WITH FA WHO VOLUNTEER TO SUPPORT FARA'S MISSION, GREW TO 100 MEMBERS FROM COUNTRIES AROUND THE WORLD. AMBASSADORS NOW REPRESENT 14 COUNTRIES GLOBALLY PLUS 32 STATES THROUGHOUT THE US.TO HELP FURTHER FARA'S AWARENESS AND OUTREACH INITIATIVES, FARA ALSO FUNDED A GRANT FOR THE CREATION OF A DOCUMENTARY FILM ABOUT HOW THE FA COMMUNITY UNITES TO ADVANCE RESEARCH. THE FILM, UNDER THE WORKING TILE "THE HIGHEST ROAD," FOCUSES ON THE FA COMMUNITY'S ROLE IN HELPING TO GET THE FIRST DRUG APPROVED FOR FA A STORY THAT IS TOLD IN PARALLEL WITH COMMUNITY MEMBERS ATTEMPTING TO CYCLE UP THE HIGHEST PAVED ROAD IN INDIA. THE FILM IS CURRENTLY IS POST PRODUCTION WITH THE AIM TO BE SHOWN IN FILM FESTIVALS IN 2026.Expenses $491,179 · grants $80,000
- WORKSHOPS, SYMPOSIA, & CONFERENCESINTERNATIONAL CONGRESS FOR ATAXIA RESEARCHIN NOVEMBER 2024, THE INTERNATIONAL CONGRESS FOR ATAXIA RESEARCH (ICAR) BROUGHT TOGETHER OVER 600 RESEARCHERS FROM AROUND THE WORLD. IT WAS THE LARGEST ICAR TO DATE AND A POWERFUL EXAMPLE OF HOW WE ACCELERATE PROGRESS WHEN EXPERTS ACROSS DIFFERENT TYPES OF ATAXIA COME TOGETHER TO SHARE IDEAS AND COLLABORATE. FARA WAS HONORED TO CO-HOST THE MEETING ALONG WITH ATAXIA UK, NATIONAL ATAXIA FOUNDATION, AND THE ATAXIA GLOBAL INITIATIVE.THIS YEAR'S PROGRAM INCLUDED A MIX OF PLENARY SESSIONS, BREAKOUT WORKSHOPS, AND SCIENTIFIC DEBATE. THE DEBATE SPARKED THOUGHTFUL DISCUSSION ABOUT THE STRENGTHS OF IN VIVO VS. IN VITRO RESEARCH MODELS AND HIGHLIGHTED HOW BOTH APPROACHES HELP TO MOVE THE SCIENCE FORWARD.SOME INSIGHTS AND LEARNINGS FROM ICAR 2024 INCLUDED: 1. DISCOVERING THAT FRATAXIN ACTIVITY CAN BE BOOSTED BY TARGETING OTHER COMPONENTS OF THE IRON-SULFUR CLUSTER ASSEMBLY REVEALS A POTENTIAL NEW TREATMENT PATHWAY. 2. SOME GAA REPEAT INTERRUPTIONS ARE MORE COMMON THAN PREVIOUSLY KNOWN, IMPACTING CARRIER DETECTION AND OPENING NEW THERAPEUTIC OPPORTUNITIES. 3. INFLAMMATION MIGHT CONTRIBUTE TO NERVE DAMAGE IN FA. 4.CAPSID FOR AN IV GENE ADDITION THERAPY REACHED KEY BRAIN AND HEART AREAS IN ANIMAL MODELS 5. MULTIPLE THERAPIES ACROSS DIFFERENT MECHANISMS OF ACTION ARE SHOWING EARLY PROMISE.FARA ALSO HOSTED FIVE RESEARCH RECEPTIONS AND SYMPOSIUMS TO SHARE INFORMATION ABOUT THE FA DRUG DEVELOPMENT PIPELINE, ONGOING CLINICAL TRIALS, CLINICAL MANAGEMENT, AND FARA RESOURCES. VIRTUAL EDUCATION SESSIONS INCLUDED FLASH TALKS WITH FARA-FUNDED RESEARCHERS, COMMUNITY CONVERSATION WEBINARS WITH FARA LEADERSHIP, AND INFORMATION SESSIONS WITH PHARMACEUTICAL PARTNERS.Expenses $357,617
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | Not on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 52-2122720
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 1999
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Medical research (H99)
- Assets (IRS master file)
- $6,946,549
- Income (IRS master file)
- $14,956,926
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2024 | $13,135,426 | $13,277,236 | $6,946,549 | IRS |
| 990 | December 2023 | $11,203,043 | $12,200,773 | $7,752,276 | XML |
| 990 | December 2022 | $11,042,911 | $11,132,747 | $7,260,774 | IRS |
| 990 | December 2021 | – | – | – | IRS |
| 990 | December 2020 | – | – | – | IRS |
| 990 | December 2019 | – | – | – | IRS |
| 990 | December 2018 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 52-2122720).
Questions about FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA
- What is the EIN of FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA?
- The employer identification number (EIN) of FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA is 52-2122720.
- Is FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1999.
- Are donations to FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA due?
- The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2024.
- Who is the principal officer of FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA?
- The 990 for the year ended December 31, 2024 names JENNIFER FARMER.
- Who are the officers and directors of FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA?
- The 990 for the year ended December 31, 2024 lists 23 people; 6 received compensation from the organization, the highest $250,000 (BARBARA A TATE, CHIEF SCIENTIFIC OFFICER).
- How much revenue does FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA have?
- On its 990 for the year ended December 31, 2024 it reported revenue of $13,135,426, expenses of $13,277,236 and total assets of $6,946,549 at year end.
Other nonprofits in DOWNINGTOWN
- ST JOHN VIANNEY CENTER EIN 23-1396815 · last filed 990 for 2025
- MISSION FOR EDUCATING CHILDREN WITH AUTISM EIN 23-2906372 · last filed 990 for 2025
- MINQUAS FIRE COMPANY 2 INC EIN 23-0534530 · last filed 990 for 2024
- LORD S PANTRY OF DOWNINGTOWN EIN 23-3092880 · last filed 990 for 2025
- CHESCONET EIN 23-2930577 · last filed 990 for 2025
- PEACEMAKER CENTER INC EIN 23-3023837 · last filed 990 for 2025
- CHILDRENS COUNTRY WEEK ASSOCIATION EIN 23-0470750 · last filed 990 for 2024
- CERTIFICATION BOARD FOR MUSIC THERAPISTS EIN 52-1350826 · last filed 990 for 2024
All nonprofits in DOWNINGTOWN · Pennsylvania · Medical research